arrow
M

Michael Zöller

LMU University Hospital
H指数:29
被引数:3,001

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Data on the Effectiveness and Use of Intravenous Fosfomycin for the Treatment of Difficult-to-Treat Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria—A Subgroup Analysis from the FORTRESS Study

真实世界数据:静脉注射磷霉素治疗由碳青霉烯耐药革兰氏阴性菌引起的难治性感染的有效性与使用情况——来自FORTRESS研究的亚组分析

2026-08-140
OA
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization

β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度(MICcBLI)作为评估哌拉西林/他唑巴坦药代动力学/药效学关系以优化给药剂量的方法学

2025-11-010
PRE
Towards model-informed precision dosing of intravenous linezolid: a multicentre external evaluation of pharmacokinetic models in critically ill adults

面向注射用利奈唑胺模型指导的精确给药:一项针对重症成人患者药代动力学模型的多中心外部评估

2025-09-090
PRE
Model-informed identification of optimised dosing strategies for meropenem in critically ill patients receiving SLEDD: an observational study

基于模型识别的危重症患者接受SLEDD治疗时美罗培南优化给药策略:一项观察性研究

2025-04-250
OA
Real-World Use, Effectiveness, and Safety of Intravenous Fosfomycin: The FORTRESS Study

静脉注射磷霉素的真实世界应用、有效性与安全性:FORTRESS研究

2025-03-191
OA
Can Mobilising Specialists be Relieved by a Robotic System for the Early Mobilisation of Intensive-Care Patients? A Quantitative Longitudinal Study at Two Data Collection Points at a German University Hospital
2025-01-310
OA
Reply to Gatti and Pea, Are the pharmacokinetic data of meropenem studied in CSF of a mixed population composed of patients with cerebral infections and patients with extracerebral infections really helpful for clinicians treating CNS infections?
2024-12-050
PRE
Meropenem pharmacokinetics in cerebrospinal fluid: comparing intermittent and continuous infusion strategies in critically ill patients-a prospective cohort study
2024-09-042
PRE